nodes	percent_of_prediction	percent_of_DWPC	metapath
Altretamine—Alkylating Activity—Mechlorethamine—lymphatic system cancer	0.561	0.591	CiPCiCtD
Altretamine—Alkylating Activity—Carmustine—lymphatic system cancer	0.389	0.409	CiPCiCtD
Altretamine—Affective disorder—Mitoxantrone—lymphatic system cancer	0.0048	0.095	CcSEcCtD
Altretamine—Neurotoxicity—Teniposide—lymphatic system cancer	0.00297	0.0587	CcSEcCtD
Altretamine—Neurotoxicity—Fludarabine—lymphatic system cancer	0.00261	0.0516	CcSEcCtD
Altretamine—Myelosuppression—Teniposide—lymphatic system cancer	0.00245	0.0486	CcSEcCtD
Altretamine—Myelosuppression—Fludarabine—lymphatic system cancer	0.00216	0.0427	CcSEcCtD
Altretamine—Neurotoxicity—Vincristine—lymphatic system cancer	0.00159	0.0315	CcSEcCtD
Altretamine—Myelosuppression—Bleomycin—lymphatic system cancer	0.00158	0.0313	CcSEcCtD
Altretamine—Myelosuppression—Carmustine—lymphatic system cancer	0.00138	0.0273	CcSEcCtD
Altretamine—Myelosuppression—Vincristine—lymphatic system cancer	0.00132	0.0261	CcSEcCtD
Altretamine—Myelosuppression—Mitoxantrone—lymphatic system cancer	0.00128	0.0254	CcSEcCtD
Altretamine—Neoplasm—Teniposide—lymphatic system cancer	0.00104	0.0206	CcSEcCtD
Altretamine—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.00093	0.0184	CcSEcCtD
Altretamine—Neurotoxicity—Methotrexate—lymphatic system cancer	0.000773	0.0153	CcSEcCtD
Altretamine—Pancytopenia—Teniposide—lymphatic system cancer	0.000686	0.0136	CcSEcCtD
Altretamine—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.000631	0.0125	CcSEcCtD
Altretamine—Vertigo—Mechlorethamine—lymphatic system cancer	0.000613	0.0121	CcSEcCtD
Altretamine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.000611	0.0121	CcSEcCtD
Altretamine—Pancytopenia—Fludarabine—lymphatic system cancer	0.000603	0.0119	CcSEcCtD
Altretamine—Neoplasm—Carmustine—lymphatic system cancer	0.000585	0.0116	CcSEcCtD
Altretamine—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.000555	0.011	CcSEcCtD
Altretamine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.000545	0.0108	CcSEcCtD
Altretamine—Anorexia—Mechlorethamine—lymphatic system cancer	0.000531	0.0105	CcSEcCtD
Altretamine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.000484	0.00958	CcSEcCtD
Altretamine—Anaemia—Teniposide—lymphatic system cancer	0.000465	0.0092	CcSEcCtD
Altretamine—Leukopenia—Teniposide—lymphatic system cancer	0.00045	0.00891	CcSEcCtD
Altretamine—Pancytopenia—Bleomycin—lymphatic system cancer	0.000442	0.00874	CcSEcCtD
Altretamine—Ataxia—Carmustine—lymphatic system cancer	0.000442	0.00874	CcSEcCtD
Altretamine—Ataxia—Vincristine—lymphatic system cancer	0.000422	0.00835	CcSEcCtD
Altretamine—Anaemia—Fludarabine—lymphatic system cancer	0.000409	0.00809	CcSEcCtD
Altretamine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000402	0.00795	CcSEcCtD
Altretamine—Leukopenia—Fludarabine—lymphatic system cancer	0.000396	0.00783	CcSEcCtD
Altretamine—Anorexia—Teniposide—lymphatic system cancer	0.000391	0.00774	CcSEcCtD
Altretamine—Pancytopenia—Carmustine—lymphatic system cancer	0.000386	0.00763	CcSEcCtD
Altretamine—Convulsion—Fludarabine—lymphatic system cancer	0.000383	0.00758	CcSEcCtD
Altretamine—Pancytopenia—Vincristine—lymphatic system cancer	0.000368	0.00729	CcSEcCtD
Altretamine—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000359	0.00709	CcSEcCtD
Altretamine—Decreased appetite—Teniposide—lymphatic system cancer	0.000357	0.00706	CcSEcCtD
Altretamine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000355	0.00702	CcSEcCtD
Altretamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.000354	0.00701	CcSEcCtD
Altretamine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000353	0.00699	CcSEcCtD
Altretamine—Anorexia—Fludarabine—lymphatic system cancer	0.000344	0.00681	CcSEcCtD
Altretamine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000339	0.0067	CcSEcCtD
Altretamine—Nausea—Mechlorethamine—lymphatic system cancer	0.000331	0.00655	CcSEcCtD
Altretamine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000314	0.00621	CcSEcCtD
Altretamine—Fatigue—Fludarabine—lymphatic system cancer	0.000311	0.00616	CcSEcCtD
Altretamine—Anaemia—Bleomycin—lymphatic system cancer	0.0003	0.00593	CcSEcCtD
Altretamine—Asthenia—Teniposide—lymphatic system cancer	0.000295	0.00583	CcSEcCtD
Altretamine—Leukopenia—Bleomycin—lymphatic system cancer	0.00029	0.00574	CcSEcCtD
Altretamine—Neoplasm—Methotrexate—lymphatic system cancer	0.000271	0.00536	CcSEcCtD
Altretamine—Anaemia—Carmustine—lymphatic system cancer	0.000262	0.00518	CcSEcCtD
Altretamine—Vomiting—Teniposide—lymphatic system cancer	0.000261	0.00517	CcSEcCtD
Altretamine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000259	0.00513	CcSEcCtD
Altretamine—Asthenia—Fludarabine—lymphatic system cancer	0.000259	0.00512	CcSEcCtD
Altretamine—Leukopenia—Carmustine—lymphatic system cancer	0.000253	0.00501	CcSEcCtD
Altretamine—Anorexia—Bleomycin—lymphatic system cancer	0.000252	0.00499	CcSEcCtD
Altretamine—Anaemia—Vincristine—lymphatic system cancer	0.00025	0.00494	CcSEcCtD
Altretamine—Convulsion—Carmustine—lymphatic system cancer	0.000245	0.00485	CcSEcCtD
Altretamine—Nausea—Teniposide—lymphatic system cancer	0.000244	0.00483	CcSEcCtD
Altretamine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000243	0.00481	CcSEcCtD
Altretamine—Vertigo—Vincristine—lymphatic system cancer	0.000243	0.0048	CcSEcCtD
Altretamine—Leukopenia—Vincristine—lymphatic system cancer	0.000242	0.00478	CcSEcCtD
Altretamine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000235	0.00466	CcSEcCtD
Altretamine—Convulsion—Vincristine—lymphatic system cancer	0.000234	0.00463	CcSEcCtD
Altretamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00023	0.00455	CcSEcCtD
Altretamine—Vomiting—Fludarabine—lymphatic system cancer	0.000229	0.00454	CcSEcCtD
Altretamine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000228	0.00451	CcSEcCtD
Altretamine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000226	0.00447	CcSEcCtD
Altretamine—Anorexia—Carmustine—lymphatic system cancer	0.00022	0.00436	CcSEcCtD
Altretamine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000216	0.00427	CcSEcCtD
Altretamine—Nausea—Fludarabine—lymphatic system cancer	0.000214	0.00424	CcSEcCtD
Altretamine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00021	0.00416	CcSEcCtD
Altretamine—Anorexia—Vincristine—lymphatic system cancer	0.00021	0.00416	CcSEcCtD
Altretamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000205	0.00405	CcSEcCtD
Altretamine—Ataxia—Methotrexate—lymphatic system cancer	0.000205	0.00405	CcSEcCtD
Altretamine—Decreased appetite—Carmustine—lymphatic system cancer	0.000201	0.00397	CcSEcCtD
Altretamine—Decreased appetite—Vincristine—lymphatic system cancer	0.000192	0.00379	CcSEcCtD
Altretamine—Fatigue—Vincristine—lymphatic system cancer	0.00019	0.00376	CcSEcCtD
Altretamine—Asthenia—Bleomycin—lymphatic system cancer	0.00019	0.00376	CcSEcCtD
Altretamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000187	0.00369	CcSEcCtD
Altretamine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000185	0.00366	CcSEcCtD
Altretamine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000179	0.00353	CcSEcCtD
Altretamine—Vomiting—Bleomycin—lymphatic system cancer	0.000168	0.00333	CcSEcCtD
Altretamine—Asthenia—Carmustine—lymphatic system cancer	0.000166	0.00328	CcSEcCtD
Altretamine—Asthenia—Vincristine—lymphatic system cancer	0.000158	0.00313	CcSEcCtD
Altretamine—Nausea—Bleomycin—lymphatic system cancer	0.000157	0.00311	CcSEcCtD
Altretamine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000154	0.00305	CcSEcCtD
Altretamine—Dizziness—Carmustine—lymphatic system cancer	0.000153	0.00302	CcSEcCtD
Altretamine—Vomiting—Carmustine—lymphatic system cancer	0.000147	0.00291	CcSEcCtD
Altretamine—Dizziness—Vincristine—lymphatic system cancer	0.000146	0.00288	CcSEcCtD
Altretamine—Vomiting—Vincristine—lymphatic system cancer	0.00014	0.00277	CcSEcCtD
Altretamine—Nausea—Carmustine—lymphatic system cancer	0.000137	0.00271	CcSEcCtD
Altretamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000137	0.0027	CcSEcCtD
Altretamine—Nausea—Vincristine—lymphatic system cancer	0.000131	0.00259	CcSEcCtD
Altretamine—Nausea—Mitoxantrone—lymphatic system cancer	0.000128	0.00252	CcSEcCtD
Altretamine—Anaemia—Methotrexate—lymphatic system cancer	0.000121	0.0024	CcSEcCtD
Altretamine—Vertigo—Methotrexate—lymphatic system cancer	0.000118	0.00233	CcSEcCtD
Altretamine—Leukopenia—Methotrexate—lymphatic system cancer	0.000117	0.00232	CcSEcCtD
Altretamine—Convulsion—Methotrexate—lymphatic system cancer	0.000114	0.00225	CcSEcCtD
Altretamine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000105	0.00207	CcSEcCtD
Altretamine—Anorexia—Methotrexate—lymphatic system cancer	0.000102	0.00202	CcSEcCtD
Altretamine—Decreased appetite—Methotrexate—lymphatic system cancer	9.3e-05	0.00184	CcSEcCtD
Altretamine—Fatigue—Methotrexate—lymphatic system cancer	9.22e-05	0.00182	CcSEcCtD
Altretamine—Asthenia—Methotrexate—lymphatic system cancer	7.68e-05	0.00152	CcSEcCtD
Altretamine—Dizziness—Methotrexate—lymphatic system cancer	7.07e-05	0.0014	CcSEcCtD
Altretamine—Vomiting—Methotrexate—lymphatic system cancer	6.8e-05	0.00135	CcSEcCtD
Altretamine—Nausea—Methotrexate—lymphatic system cancer	6.35e-05	0.00126	CcSEcCtD
